STOCK TITAN

XOMA Corp - XOMA STOCK NEWS

Welcome to our dedicated news page for XOMA (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XOMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XOMA's position in the market.

Rhea-AI Summary
XOMA Corporation announces earning a $5 million milestone for the FDA acceptance of Day One Biopharmaceuticals' New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has granted Priority Review and set a PDUFA date of April 30, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
clinical trial
-
Rhea-AI Summary
XOMA Corporation announces cash dividends for Series A and Series B Cumulative Preferred Stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.26%
Tags
dividends
-
Rhea-AI Summary
XOMA Corporation announces cash dividends for Series A and Series B Cumulative Preferred Stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
dividends
Rhea-AI Summary
XOMA Corporation announces cash dividends for Series A and Series B Cumulative Preferred Stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
dividends
-
Rhea-AI Summary
XOMA Corporation to present company update at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
-
Rhea-AI Summary
XOMA Corporation to present company update at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences
Rhea-AI Summary
XOMA Corporation to present company update at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
earnings
XOMA Corp

Nasdaq:XOMA

XOMA Rankings

XOMA Stock Data

279.60M
7.95M
0.36%
66.58%
2.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Berkeley

About XOMA

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.